Orange County Retina Medical Group | Santa Ana, CA

Research site

(Unclaimed)

Location

999 North Tustin Avenue Suite 17, Santa Ana, California, United States of America

Site insights

Top conditions

Top treatments

KSI-301

Triamcinolone Acetonide

Axitinib

APL-2

Aflibercept

Ranibizumab

Bevasiranib

ABP 938

Faricimab

ANX007

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

10 of 30 total trials

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration

Enrolling

Macular Neovascularization Secondary to Age-Related Macular Degeneration

Biological: 4D-150 IVT (3E10 vg/eye)

Biological: EYLEA® (aflibercept) Injection 2 mg (0.05mL)

A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm (PAVILION)

Study GR41675 is a Multicenter, Randomized Study in Participants with Diabetic Retinopathy (DR) Without Center-Involved Diabetic Macular Edema (CI-DM...

Active, not recruiting

Diabetic Retinopathy

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Intravitreal Ranibizumab 0.5 mg Injection

Locations recently updated

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy (SIENNA)

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atroph...

Enrolling

Age-related Macular Degeneration (AMD)

Geographic Atrophy (GA)

Drug: Placebo

Drug: Pozelimab

Status recently updated

A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA) (ARCHER II)

The primary purpose of the study is to determine if IVT injections of vonaprument every month reduce vision loss in participants with GA secondary to...

Enrolling

Active, not recruiting

Geographic Atrophy

Drug: Vonaprument

Other: Sham Administration

A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (CONSTANCE)

This study is a Phase IIIb/IV, multicenter, randomized, two-arm, open-label 100-week study to investigate the efficacy, safety, and durability of int...

Active, not recruiting

Neovascular Age-related Macular Degeneration (nAMD)

Drug: Faricimab

A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME (Pagoda)

This study will evaluate the efficacy, safety, and Pharmacokinetics (PK) of the PDS with ranibizumab in participants with DME when treated every 24 w...

Enrolling

Diabetic Macular Edema

Drug: PDS Implant Pre-Filled with 100 mg/mL Ranibizumab

Drug: Ranibizumab refill exchange

Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD (ATMOSPHERE)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Choroidal Neovascularization

Wet Age-related Macular Degeneration

Genetic: ABBV-RGX-314

Biological: Ranibizumab (LUCENTIS®)

Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT)

ABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular d...

Enrolling

Wet Age-related Macular Degeneration

WetAMD

Genetic: ABBV-RGX-314 Dose 1

Biological: Aflibercept (EYLEA®)